
The Zhitong Finance App learned that Citi released a research report saying that H&H International Holdings (01112) management maintains strong profit guidelines for 2026 and is optimistic about the outlook for 2027. Management is confident that, driven by strong growth in early products, the 10% growth in infant formula (IMF) will be maintained by continuing to expand market share and improve customer conversion. In addition to revenue growth, financing costs have declined due to continued deleveraging, which is expected to provide strong support for profits. The bank gave the company a “buy” rating, and the target price was HK$31.4.
The bank said that management guided revenue growth in 2026 by ten digits, EBITDA profit margins in the middle to high ten digits, and adjusted net interest rates in the middle to high single digits. In terms of segments, adult nutrition and care products (ANC) are expected to record low 10-digit revenue growth and an EBITDA profit margin of about 20%; infant nutrition (BNC) is expected to increase by more than 40%, and EBITDA profit margins are medium to high ten digits; and pet nutrition (PNC) is expected to record low to mid-single digit growth and medium single-digit EBITDA profit margins.
Looking ahead to 2027, management expects each business segment to remain the driving force for growth. The benchmark scenario for infant formula revenue growth is about 10%, and the EBITDA profit margin is generally stable. The company plans to repay the debt of 500 million to 700 million yuan and reaffirms that it will maintain a 50% dividend ratio. The target net debt to EBITDA ratio is about 2 times. Management expects financing costs to drop by at least 50 million yuan in 2027, benefiting from debt repayment and potential credit rating improvements.